Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer

Lung Cancer

Volumn 71, Issue 2, 2011, Pages 186-190

  Kim, Anthony W ^a   Batus, Marta ^b   Myint, Ronald ^b   Fidler, Mary J ^b   Basu, Sanjib ^b   Bonomi, Philip ^b   Faber, L Penfield ^b   Wightman, Sean C ^b   Warren, William H ^b   McIntire, Maria ^b   Arvanitis, Leonidas D ^b   Gattuso, Paolo ^b   Xu, Xiulong ^b   Liptay, Michael J ^b  

^a YALE UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Non small cell lung cancer; Surgery; Xanthine oxidoreductase

Indexed keywords

XANTHINE OXIDASE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STAINING;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; XANTHINE DEHYDROGENASE;

EID: 78650945133     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.05.006     Document Type: Article

References (30)

1. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359(13):1367-1380.
2. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26(21):3552-3559.
3. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350(4):351-360.
4. Fouret P., Planchard D., Mendiboure J., Kamal N.S., Olaussen K.A., Bertrand P., et al. MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer. J Clin Oncol 2009, 27(18S: Suppl.). abstr CRA7502.
5. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
6. Harrison R. Structure and function of xanthine oxidoreductase: where are we now?. Free Radic Biol Med 2002, 33(6):774-797.
7. McManaman J.L., Palmer C.A., Wright R.M., Neville M.C. Functional regulation of xanthine oxidoreductase expression and localization in the mouse mammary gland: evidence of a role in lipid secretion. J Physiol 2002, 545(Pt 2):567-579.
8. Vorbach C., Scriven A., Capecchi M.R. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes Dev 2002, 16(24):3223-3235.
9. Kurosaki M., Zanotta S., Li Calzi M., Garattini E., Terao M. Expression of xanthine oxidoreductase in mouse mammary epithelium during pregnancy and lactation: regulation of gene expression by glucocorticoids and prolactin. Biochem J 1996, 319(Pt 3):801-810.
10. Linder N., Lundin J., Isola J., Lundin M., Raivio K.O., Joensuu H. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res 2005, 11(12):4372-4381.
11. Durak I., Beduk Y., Kavutcu M., Ozturk S., Canbolat O., Ulutepe S. Activities of superoxide dismutase and glutathione peroxidase enzymes in cancerous and non-cancerous human kidney tissues. Int Urol Nephrol 1997, 29(1):5-11.
12. Ikegami T., Natsumeda Y., Weber G. Decreased concentration of xanthine dehydrogenase (EC 1.1.1.204) in rat hepatomas. Cancer Res 1986, 46(8):3838-3841.
13. Prajda N., Weber G. Malignant transformation-linked imbalance: decreased xanthine oxidase activity in hepatomas. FEBS Lett 1975, 59(2):245-249.
14. Kurosaki M., Li Calzi M., Scanziani E., Garattini E., Terao M. Tissue- and cell-specific expression of mouse xanthine oxidoreductase gene in vivo: regulation by bacterial lipopolysaccharide. Biochem J 1995, 306(Pt 1):225-234.
15. Terao M., Kurosaki M., Zanotta S., Garattini E. The xanthine oxidoreductase gene: structure and regulation. Biochem Soc Trans 1997, 25(3):791-796.
16. Chang G.C., Hsu S.L., Tsai J.R., Wu W.J., Chen C.Y., Sheu G.T. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol 2004, 502(3):169-183.
17. Wang X., Martindale J.L., Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000, 275(50):39435-39443.
18. Linder N., Haglund C., Lundin M., Nordling S., Ristimaki A., Kokkola A., et al. Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol 2006, 59(9):965-971.
19. Prajda N., Morris H.P., Weber G. Imbalance of purine metabolism in hepatomas of different growth rates as expressed in behavior of xanthine oxidase (EC 1.2.3.2). Cancer Res 1976, 36(12):4639-4646.
20. Stirpe F., Ravaioli M., Battelli M.G., Musiani S., Grazi G.L. Xanthine oxidoreductase activity in human liver disease. Am J Gastroenterol 2002, 97(8):2079-2085.
21. Weber G., Hager J.C., Lui M.S., Prajda N., Tzeng D.Y., Jackson R.C., et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts. Cancer Res 1981, 41(3):854-859.
22. Weber G. Enzymes of purine metabolism in cancer. Clin Biochem 1983, 16(1):57-63.
23. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981, 78(11):6858-6862.
24. Hiatt R.A., Fireman B.H. Serum uric acid unrelated to cancer incidence in humans. Cancer Res 1988, 48(10):2916-2918.
25. Bozkir A., Simsek B., Gungort A., Torun M. Ascorbic acid and uric acid levels in lung cancer patients. J Clin Pharm Ther 1999, 24(1):43-47.
26. Kolonel L.N., Yoshizawa C., Nomura A.M., Stemmermann G.N. Relationship of serum uric acid to cancer occurrence in a prospective male cohort. Cancer Epidemiol Biomarkers Prev 1994, 3(3):225-228.
27. Dent P., Yacoub A., Fisher P.B., Hagan M.P., Grant S. MAPK pathways in radiation responses. Oncogene 2003, 22(37):5885-5896.
28. Schmidt-Ullrich R.K., Dent P., Grant S., Mikkelsen R.B., Valerie K. Signal transduction and cellular radiation responses. Radiat Res 2000, 153(3):245-257.
29. Nelson J.M., Fry D.W. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 2001, 276(18):14842-14847.
30. Woessmann W., Chen X., Borkhardt A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol 2002, 50(5):397-404.